Acute Antibody-Mediated Rejection in Kidney Transplantation: Clinical and Therapeutic Aspects
Salvadori M* and Bertoni E
Dept of Transplantation, Careggi University Hospital, Florence, Italy
- *Corresponding Author:
- Maurizio Salvadori
professor of Nephrology, Careggi University Hospital
Viale Pieraccini 18 50139, Florence, Italy
Tel: +39 055 597151
Fax: +39 055 597151
E-mail: [email protected]
Received Date: December 11, 2013; Accepted Date: December 24, 2013; Published Date: December 27, 2013
Citation: Salvadori M, Bertoni E (2013) Acute Antibody-Mediated Rejection in Kidney Transplantation: Clinical and Therapeutic Aspects. J Nephrol Ther 4:146. doi:10.4172/2161-0959.1000146
Copyright: © 2013 Salvadori M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Acute Antibody Mediated Rejection (ABMR) in kidney transplantation is a severe complication that frequently occurs after transplantation and is due either to pre-transplant Donor-Specific Antibodies (DSAs) or to de novo DSAs. New techniques to detect DSAs in the recipient serum and advances in the assessment of graft pathology have allowed us to recognize this entity in recent years.
The treatment of ABMR is a multistep process consisting of the desensitization of the patients with preformed
antibodies to prevent acute ABMR: in cases of acute ABMR, the antibodies are removed from the serum and anti-B cells immunosuppressants are used.